Nyrada Inc. (ASX:NYR)

Revenue by Segment

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018
Drug Development, Focusing on Small Molecules	2.40M	3.24M	1.43M	1.09M	2.34M
Drug Development, Focusing on Small Molecules Growth	-26.07%	126.72%	30.73%	-53.18%	107.57%
Total	2.40M	3.24M	1.43M	1.09M	2.34M
Total Growth	-26.07%	126.72%	30.73%	-53.18%	107.57%

Revenue by Geography

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019	Jun 30, 2018
Australasia	2.40M	3.24M	1.43M	1.09M	2.34M
Australasia Growth	-26.07%	126.72%	30.73%	-53.18%	107.57%
Total	2.40M	3.24M	1.43M	1.09M	2.34M
Total Growth	-26.07%	126.72%	30.73%	-53.18%	107.57%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 8, 2026

Data Sources Report a data error